Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1.061
No. of companies carrying out R&D in Biotechnology;250 or more employees;73
No. of companies carrying out R&D in Biotechnology;Total;1.133
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;30
%Companies according to biotechnology used: Genetic code;250 or more employees;50
%Companies according to biotechnology used: Genetic code;Total;32
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;40
%Companies according to biotechnology used: Functional units;250 or more employees;51
%Companies according to biotechnology used: Functional units;Total;41
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;26
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;46
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;27
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;47
%Companies according to biotechnology used: Bioprocesses;250 or more employees;64
%Companies according to biotechnology used: Bioprocesses;Total;48
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;8
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;20
%Companies according to biotechnology used: Sub-cellular organisms;Total;8
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;21
%Companies according to biotechnology used: Bio-computing;250 or more employees;31
%Companies according to biotechnology used: Bio-computing;Total;21
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;14
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;18
%Companies according to biotechnology used: Nanobiotechnology;Total;14
%Companies according to biotechnology used: Other;Fewer than 250 employees;13
%Companies according to biotechnology used: Other;250 or more employees;10
%Companies according to biotechnology used: Other;Total;13
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;549
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;15
Companies in which biotechnology activities are: Main and/or exclusive;Total;564
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;193
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;19
Companies in which biotechnology activities are: A secondary line of business;Total;212
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;319
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;38
Companies in which biotechnology activities are: A tool necessary for production;Total;358
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;50
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;51
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;50
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;20
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;1
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;19
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;29
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;36
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;29
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;22
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;18
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;21
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;13
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;11
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;13
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;14
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;7
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;13
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;7.883
Personnel in R&D in biotechnology (no. of persons);250 or more employees;2.823
Personnel in R&D in biotechnology (no. of persons);Total;10.706
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;4.706
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;1.521
Personnel in R&D in biotechnology (no. of persons): Researchers;Total;6.227
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;3.177
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;1.302
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total;4.479
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;4.068
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;1.727
Personnel in R&D in biotechnology (no. of persons): women;Total;5.795
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2.417
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;852
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total;3.269
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;1.652
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;875
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total;2.527
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;5.599
Personnel in R&D in biotechnology (FTE);250 or more employees;2.117,4
Personnel in R&D in biotechnology (FTE);Total;7.716,4
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;3.511,8
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;1.091,3
Personnel in R&D in biotechnology (FTE): Researchers;Total;4.603,1
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;2.087,2
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;1.026,1
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total;3.113,3
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;2.969,5
Personnel in R&D in biotechnology (FTE): women;250 or more employees;1.323,4
Personnel in R&D in biotechnology (FTE): women;Total;4.292,9
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;1.832,2
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;614,2
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total;2.446,4
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1.137,3
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;709,2
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total;1.846,5
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;452.121
Internal expenditure on R&D (thousands of euros);250 or more employees;163.932
Internal expenditure on R&D (thousands of euros);Total;616.053
1) By nature of the expense: Current expenses;Fewer than 250 employees;413.906
1) By nature of the expense: Current expenses;250 or more employees;160.340
1) By nature of the expense: Current expenses;Total;574.245
1.1) Remuneration to researchers;Fewer than 250 employees;160.779
1.1) Remuneration to researchers;250 or more employees;60.962
1.1) Remuneration to researchers;Total;221.741
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;61.960
1.2) Remuneration to technicians and assistants;250 or more employees;40.504
1.2) Remuneration to technicians and assistants;Total;102.464
1.3) Other current expenses;Fewer than 250 employees;191.167
1.3) Other current expenses;250 or more employees;58.874
1.3) Other current expenses;Total;250.041
2) By nature of the expense: Capital expenses;Fewer than 250 employees;38.215
2) By nature of the expense: Capital expenses;250 or more employees;3.593
2) By nature of the expense: Capital expenses;Total;41.808
2.1) Land and buildings;Fewer than 250 employees;4.988
2.1) Land and buildings;250 or more employees;371
2.1) Land and buildings;Total;5.359
2.2) Equipment and instruments;Fewer than 250 employees;26.997
2.2) Equipment and instruments;250 or more employees;2.493
2.2) Equipment and instruments;Total;29.489
2.3) Acquisition of specific R&D software;Fewer than 250 employees;1.716
2.3) Acquisition of specific R&D software;250 or more employees;590
2.3) Acquisition of specific R&D software;Total;2.306
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;4.515
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;139
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;4.654
1) By origin of the funds: National funds;Fewer than 250 employees;388.127
1) By origin of the funds: National funds;250 or more employees;123.833
1) By origin of the funds: National funds;Total;511.960
1.1) Own funds;Fewer than 250 employees;294.928
1.1) Own funds;250 or more employees;87.407
1.1) Own funds;Total;382.335
1.2) From companies;Fewer than 250 employees;29.072
1.2) From companies;250 or more employees;15.952
1.2) From companies;Total;45.024
1.3) Public Administration funds;Fewer than 250 employees;60.976
1.3) Public Administration funds;250 or more employees;11.410
1.3) Public Administration funds;Total;72.387
1.4) From Universities;Fewer than 250 employees;363
1.4) From Universities;250 or more employees;0
1.4) From Universities;Total;363
1.5) From non profit private institutions;Fewer than 250 employees;2.788
1.5) From non profit private institutions;250 or more employees;9.064
1.5) From non profit private institutions;Total;11.851
1) By origin of the funds: Foreign funds;Fewer than 250 employees;63.994
1) By origin of the funds: Foreign funds;250 or more employees;40.100
1) By origin of the funds: Foreign funds;Total;104.093
2.1) From EU programmes;Fewer than 250 employees;18.363
2.1) From EU programmes;250 or more employees;3.462
2.1) From EU programmes;Total;21.825
2.2) Other foreign funds;Fewer than 250 employees;45.631
2.2) Other foreign funds;250 or more employees;36.638
2.2) Other foreign funds;Total;82.269
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;88.908
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;55.434
Purchase of R&D services in biotechnology (thousands of euros);Total;144.342
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;35.758
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;34.700
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;70.458
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;53.150
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;20.734
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;73.885
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;49
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;29
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;48
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;15
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;15
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;12
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;12
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;10
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;36
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;35
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;36
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;49
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;39
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;49
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;18
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;18
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;16
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;12
% Companies that have requested biotechnology patents in Biotechnology;Total;16
Number of patents requested;Fewer than 250 employees;570
Number of patents requested;250 or more employees;63
Number of patents requested;Total;633
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;24,2
% Companies with income of an international origin related to biotechnological activities;250 or more employees;20,7
% Companies with income of an international origin related to biotechnological activities;Total;24
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;6,1
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0,9
% Turnover representing income of an international origin related to biotechnological activities;Total;1,4
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;37,3
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;75,7
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;57,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;62,7
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;24,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;42,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;96,3
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;69,4
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;82,3
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;2,4
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;29,4
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;16,5
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;1,1
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;0,9
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;1
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;0,2
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0,3
% Income of an international origin related with activities according to the classification: Other;Total;0,3